NYXH Nyxoah S.A.
USHealthcareAs of 2026-07-09 16:00
Why NYXH matters now
Nyxoah S.A. (NYXH) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.67 with +0.00% on the session and $66.1M in market capitalization; recent performance reads 1-month -43.06% and YTD -65.22%.
The latest financial table shown here is Q1 2026, with revenue of $7.4M, net income of $-18.4M, and EPS of $-0.37. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -132.7%.
The latest indexable market news headline is "Nyxoah SA (NYXH) Analyst/Investor Day Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Hold with a median target of $5.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.67
P/S
3.38
EV/EBITDA
-1.02
DCF Value
$-90.69
FCF Yield
-132.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
48.3%
Operating Margin
-527.2%
Net Margin
-527.8%
ROE
-164.4%
ROA
-87.9%
ROIC
-116.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $7.4M | $-18.4M | $-0.37 |
| Q4 2025 | $5.6M | $-23.5M | $-0.59 |
| FY 2025 | $10.0M | $-90.1M | $-2.37 |
| Q3 2025 | $2.0M | $-23.6M | $-0.63 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$3.00 - $7.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
BE
Exchange
—
Beta
0.89
Nyxoah S.A. is a medical technology company dedicated to developing and bringing to market therapies for sleep disordered breathing conditions. Its flagship offering is the Genio system, a CE-Marked, patient-focused hypoglossal neurostimulation therapy that addresses moderate to severe obstructive sleep apnea. Established in 2009, the company maintains its headquarters in Mont-Saint-Guibert, Belgium.